Decision On Bayer Probiotic Claim Could Weaken FTC Argument For Clinical Trials
This article was originally published in The Tan Sheet
FTC attempts through litigation, rather than rulemaking to establish RCTs as the standard for supplement claims, industry stakeholders say. The decision shows FTC “may not attempt to apply new standards … through contempt and threats of contempt,” says Jonathan Cohn, lead counsel for Bayer in the litigation.
You may also be interested in...
On behalf of the FTC, DoJ alleges Bayer violated a 2007 settlement to substantiate supplement claims and asks a court to require the firm to provide two RCTs for dietary supplement claims for Phillips’ Colon Health. Trade groups rally behind the firm, arguing the requirement is unfair and illegal.
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.